1254981-62-8 Usage
Chemical structure
The compound has a complex and unique structure, consisting of a spiro ring system with a fused furanopyridine moiety and a piperidine ring.
Benzyl group
A benzyl group is attached to the spiro carbon, adding an aromatic functionality to the compound.
Potential applications
The compound has potential applications in medicinal chemistry and drug development due to its diverse structural features.
Biological activity
The diverse structural features of the compound may contribute to its biological activity, although further research is needed to explore this aspect.
Research and studies
Further research and studies are required to explore the specific properties and potential uses of 1'-benzyl-spiro[furo[2,3-b]pyridine-3(2H),4'-piperidine].
Check Digit Verification of cas no
The CAS Registry Mumber 1254981-62-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,5,4,9,8 and 1 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1254981-62:
(9*1)+(8*2)+(7*5)+(6*4)+(5*9)+(4*8)+(3*1)+(2*6)+(1*2)=178
178 % 10 = 8
So 1254981-62-8 is a valid CAS Registry Number.
1254981-62-8Relevant articles and documents
1,2,3-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
-
Page/Page column 120-121, (2010/12/17)
The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 ("mGluR2"), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.
